Want to see GB:SN full AI Analyst Report?
SN Stock Chart & Stats
1068.00 p
29.50 p(2.59%)
At close: 4:00 PM EDT
1068.00 p
29.50 p(2.59%)
Day’s Range― - ―
52-Week Range980.40 p - 1,426.59 p
Previous CloseN/A
Volume682.11K
Average Volume (3M)2.64M
Market Cap
£8.41B
Enterprise Value12.08B
Total Cash (Recent Filing)£757.91M
Total Debt (Recent Filing)£3.80B
Price to Earnings (P/E)17.6
Beta1.12
Next Earnings
Feb 23, 2027EPS Estimate
0.44Next Dividend Ex-DateN/A
Dividend Yield2.93%
Share Statistics
EPS (TTM)0.76
Shares Outstanding837,432,560
10 Day Avg. Volume2,643,872
30 Day Avg. Volume2,637,681
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)2.73
Price to Sales (P/S)2.30
P/FCF Ratio16.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£1,241.80Price Target Upside16.27% Upside
Rating ConsensusHold
Number of Analyst Covering10
EPS Forecast (FY)1.1
Revenue Forecast (FY)£6.47B
Bulls Say, Bears Say
Bulls Say
Margin Expansion And EfficiencyImproving margins and savings achieved ahead of schedule indicate stronger operating discipline and a more efficient cost base. If sustained, these gains can protect profitability against moderate revenue pressure, support reinvestment, and improve cash generation over the next several quarters.
Innovation And Product MomentumA consistent launch pipeline and progress in robotics expand Smith & Nephew’s technology offering and support future procedure adoption. New products can strengthen surgeon engagement, address portfolio gaps, and create durable growth opportunities across orthopaedics and adjacent specialties.
Improved Cash Generation And Manageable LeverageRecent cash-flow improvement provides greater capacity to fund product development, acquisitions, dividends, and buybacks without relying excessively on new borrowing. Leverage remains within management’s stated target, preserving financial flexibility while the company executes its growth and efficiency plans.
Bears Say
Lower Revenue Growth OutlookThe guidance reduction signals that near-term commercial momentum is weaker than previously expected, limiting the pace at which fixed costs and innovation investments can be leveraged. Slower growth also increases dependence on efficiency savings to deliver profit targets and raises execution pressure.
Reimbursement And Portfolio FrictionReimbursement changes and portfolio gaps are directly constraining procedure-related demand and delaying recovery in important franchises. These issues may require product adaptation, stronger clinical and payer support, or additional commercial investment, making the revenue recovery path less certain.
Uneven Cash Conversion And Rising Net DebtAlthough absolute cash generation has improved, inconsistent conversion from earnings and higher net debt reduce financial flexibility. Acquisitions, buybacks, dividends, and investment are consuming cash while operating performance is being repaired, increasing sensitivity to delays in recovery or further spending needs.
SN FAQ
What was Smith & Nephew plc’s price range in the past 12 months?
Smith & Nephew plc lowest share price was 980.40 p and its highest was 1426.59 p in the past 12 months.
What is Smith & Nephew plc’s market cap?
Smith & Nephew plc’s market cap is £8.41B.
When is Smith & Nephew plc’s upcoming earnings report date?
Smith & Nephew plc’s upcoming earnings report date is Feb 23, 2027 which is in 139 days.
How were Smith & Nephew plc’s earnings last quarter?
Smith & Nephew plc released its earnings results on Aug 04, 2026. The company reported 0.159 p earnings per share for the quarter, missing the consensus estimate of 0.347 p by -0.188 p.
Is Smith & Nephew plc overvalued?
According to Wall Street analysts Smith & Nephew plc’s price is currently Undervalued.
Does Smith & Nephew plc pay dividends?
Smith & Nephew plc pays a Semiannually dividend of 11.775 p which represents an annual dividend yield of 2.93%. See more information on Smith & Nephew plc dividends here
What is Smith & Nephew plc’s EPS estimate?
Smith & Nephew plc’s EPS estimate is 0.44.
How many shares outstanding does Smith & Nephew plc have?
Smith & Nephew plc has 837,432,560 shares outstanding.
What happened to Smith & Nephew plc’s price movement after its last earnings report?
Smith & Nephew plc reported an EPS of 0.159 p in its last earnings report, missing expectations of 0.347 p. Following the earnings report the stock price went down -6.266%.
Which hedge fund is a major shareholder of Smith & Nephew plc?
Currently, no hedge funds are holding shares in GB:SN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Smith & Nephew Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
£1,241.80 (16.27% Upside)
£1,241.80 (16.27% Upside)
Insider Transactions
Sold Shares
Worth £451.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.59%
12-Months-Change
Fundamentals
Return on Equity
2.93%
Trailing 12-Months
Asset Growth
6.35%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Smith & Nephew plc
Smith & Nephew plc, along with its subsidiaries, operates globally as a developer, manufacturer, marketer, and seller of medical technology. Its orthopaedic division offers knee implants for replacement procedures and hip implants for joint reconstruction. This segment also provides trauma and extremities products, including internal and external fixation devices crucial for stabilizing severe fractures and correcting deformities. In the sports medicine field, the company furnishes surgeons with comprehensive joint repair solutions. These encompass specialized instruments, advanced technologies, and implants necessary for minimally invasive joint surgeries, addressing soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. Additionally, its arthroscopic enabling technologies support surgical visualization and intervention inside joints, comprising fluid management equipment, high-definition cameras, digital image capture systems, scopes, light sources, and monitors. It also supplies radiofrequency, electromechanical, and mechanical tissue resection devices, along with hand instruments for removing damaged tissue, and provides ear, nose, and throat (ENT) solutions. Furthermore, Smith & Nephew delivers sophisticated advanced wound management solutions. This category features products for the treatment and prevention of acute and chronic wounds, including leg, diabetic, and pressure ulcers, burns, and post-operative wounds. Its offerings extend to advanced wound bioactives, incorporating biologics and other active technologies for debridement, dermal repair, and regeneration, as well as regenerative medicine products like skin, bone graft, and articular cartilage substitutes. The advanced wound devices portfolio includes traditional and single-use negative pressure wound therapy systems, alongside hydrosurgery devices. Primarily serving healthcare providers, Smith & Nephew plc was founded in 1856 and maintains its corporate headquarters in Watford, United Kingdom.
SN Stock 12 Month Forecast
Average Price Target
1,241.80 p
▲(16.27% Upside)
Technical Analysis
Advanced Medical Solutions
―
ConvaTec
―
Hikma Pharmaceuticals
―
PureTech Health
―
Spire Healthcare
―










